08:45 AM EDT, 03/15/2024 (MT Newswires) -- Merck ( MRK ) said Friday that a late-stage trial evaluating its immunotherapy regimen, Keytruda with chemoradiotherapy, met its primary endpoint of overall survival for newly diagnosed patients with high-risk locally advanced cervical cancer.

The study previously met another primary endpoint of progression-free survival last year, Merck ( MRK ) said.

No new safety signals were identified from the trial, the drugmaker said.

Price: 120.45, Change: -0.06, Percent Change: -0.05